A-TANGO

project duration
5 years

funding
6 million €

8 countries
14 institutions

kick-off
1st March 2021

@ATANGO_H2020

/company/a-tango

a-tango.eu

More than 10 million people suffer from decompensated cirrhosis worldwide. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure.

Effective treatment of ACLF is an urgent and unmet need.

The A-TANGO consortium tests and evaluates an innovative new treatment that aims to reduce inflammation and improve hepatocyte proliferation by repurposing TAK-242, an antagonist of toll-like receptor 4, in combination with G-CSF (granulocyte colony-stimulating factor).

We call this novel combinatorial therapy G-TAK.

Objectives

- Perform Phase II clinical studies in up to 30 European hospitals to establish the safety, pharmacokinetics, and efficacy of G-TAK
- Find reliable biomarkers for better patient stratification and increased survival
- Evaluate the results with respect to clinical outcome, treatment impact, and quality of life
- Identify economic benefits for the healthcare system, reimbursement strategies, and potential commercialisation
- Disseminate the therapeutic potential of G-TAK and increase awareness of end-stage liver disease

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096.

Photo credits keyvisual: SvetaZi